HOWLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Werewolf Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026
$1.04+0.06 (+6.12%)
Close on Oct 19, 2026
- Market cap
- $50.54M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.56 (−35.00%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $50.54M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 3.10
- Dividend yield
- –
- Free cash flow yield
- -119.29%
Fundamentals
- Net income
- -$34.61M
- EPS, diluted
- -$0.72
- Free cash flow
- -$60.29M
- Book value per share
- $0.34
- Diluted shares
- 49M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Operating income
-$31.26M
Net income
-$34.61M
EPS, diluted
-$0.72
Free cash flow
–
Reported periodTrailing twelve months